Posted by Michael Wonder on 15 Dec 2022
Fresenius Kabi receives US FDA approval for biosimilar Idacio (adalimumab)
14 February 2022 - Idacio is a citrate free formulation of adalimumab.
Fresenius Kabi announced today that the US FDA has approved its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira (adalimumab).
